Phil Greenberg, MD, is head of immunology at the Fred Hutchinson Cancer Research Center. He is an internationally-recognized expert in cancer immunotherapy. His early discoveries targeting diseases with immune T cells helped drive this rapidly expanding field.
Aude Chapuis, MD, is associate professor of immunology in the Clinical Research Division at the Fred Hutchinson Cancer Research Center. She is an expert in blood stem cell transplantation and immunotherapy.
Dr. Tom Schmitt, PhD, is scientific co-founder and associate of clinical research at Fred Hutchinson Cancer Research Center. He works on improved T-cell therapies with his team.
Jim Allison, PhD, is regental professor and executive director of the Immunotherapy Platform, at University of Texas MD Anderson Cancer Center. He has spent a storied career studying the regulation of T cell responses and developing strategies for cancer immunotherapy.
Padmanee “Pam” Sharma, MD, PhD, professor of genitourinary medical oncology and immunology, co-director for immunotherapy at University of Texas MD Anderson Cancer Center. She is a leading cancer immunotherapy translational scientist.
Rafi Ahmed, PhD, is Vaccine Center Director and professor of microbiology and immunology at Emory University. He is an internationally-recognized immunologist whose work has been incredibly influential in shaping the industry’s understanding of memory T cell differentiation and anti-viral T and B cell immunity.
David Kranz, PhD, has experience in leading research on the structure, function and engineering of T cell receptors. He has been involved in the discovery of immunotherapeutic approaches to cancer through his laboratory at the University of Illinois, Urbana-Champaign.
Dr. Susan Kaech, PhD, is professor and director of the NOMIS Center for Immunobiology and Microbial Pathogenesis and NOMIS Chair at the Salk Institute. She and her team at the Salk Institute have conducted research leading to groundbreaking discoveries within T cell therapies.